Bellus hopes to fuel up on IPO cash as it squares off with giant Merck on a rival drug

Fueled by a successful Phase I trial treating chronic cough and lured by the promise of taking their lead drug to other applications, Montreal-based Bellus Health is looking to make its debut on Nasdaq with a $60 million IPO.